bms-986016
mAbexperimental
Clinical trial activity
13 trials · 18 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Oct 14, 2013 (NCT01968109)
Timeline
Indications
Mechanism of action
- Lymphocyte activation gene 3 proteinINHIBITOR
LAG3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-lag-3 antibody
- bms 986016
- bms-986016
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04150965 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2019 | Antengene Corporation, Bristol-Myers Squibb, Emory University, Hackensack University Medical Center, Harvard University, Icahn School of Medicine at Mount Sinai, Memorial Sloan-Kettering Cancer Center, Monopar Therapeutics, Multiple Myeloma Research Consortium, University of California, San Francisco, University of Michigan, University of Texas, Galveston, Wake Forest University, Washington University in St. Louis |
| NCT03493932 | Phase 1 | Sep 24, 2018 | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT03459222 | Phase 1/Phase 2 (Phase 2) | May 25, 2018 | Bristol-Myers Squibb |
| NCT03335540 | Phase 1 | Mar 13, 2018 | Bristol-Myers Squibb |
| NCT02996110 | Phase 2 | Jan 17, 2017 | Bristol-Myers Squibb |
| NCT02966548 | Phase 1 | Nov 28, 2016 | Bristol-Myers Squibb, Ono Pharmaceuticals |
| NCT02935634 | Phase 2 | Nov 23, 2016 | Bristol-Myers Squibb |
| NCT02658981 | Phase 1 | Aug 1, 2016 | Bristol-Myers Squibb, Johns Hopkins University, National Cancer Institute (NCI) |
| NCT02750514 | Phase 2 | May 6, 2016 | Bristol-Myers Squibb |
| NCT02488759 | Phase 1/Phase 2 (Phase 2) | Oct 8, 2015 | Bristol-Myers Squibb |
| NCT02060188 | Phase 2 | Mar 7, 2014 | Bristol-Myers Squibb |
| NCT02061761 | Phase 1/Phase 2 (Phase 2) | Feb 25, 2014 | Bristol-Myers Squibb |
| NCT01968109 | Phase 1/Phase 2 (Phase 2) | Oct 14, 2013 | Bristol-Myers Squibb |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 12 | 10 | 2 | 2013 |
| Antengene Corporation | For profit | 1 | 0 | 1 | 2019 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Hackensack University Medical Center | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Monopar Therapeutics | For profit | 1 | 0 | 1 | 2019 |
| Multiple Myeloma Research Consortium | Academic/Hospital | 1 | 1 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2018 |
| Ono Pharmaceuticals | For profit | 1 | 0 | 1 | 2016 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Texas, Galveston | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Wake Forest University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2019 |
18 organizations
Page 1 / 1